Evolent Health Inc (NYSE:EVH) has been assigned a consensus recommendation of “Buy” from the eighteen research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $26.20.
EVH has been the subject of several analyst reports. MED upped their price target on shares of Evolent Health from $22.00 to $31.00 and gave the company an “outperform” rating in a research report on Monday, June 18th. SunTrust Banks upped their price target on shares of Evolent Health and gave the company a “buy” rating in a research report on Thursday, June 7th. KeyCorp upped their price target on shares of Evolent Health from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Thursday, June 7th. TheStreet upgraded shares of Evolent Health from a “d+” rating to a “c-” rating in a research report on Monday, June 4th. Finally, Piper Jaffray Companies initiated coverage on shares of Evolent Health in a research report on Monday, June 4th. They set an “overweight” rating and a $30.00 price target for the company.
Evolent Health opened at $22.40 on Tuesday, according to MarketBeat. The firm has a market capitalization of $1.80 billion, a P/E ratio of -32.14 and a beta of 1.14. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.12. Evolent Health has a 52 week low of $10.30 and a 52 week high of $27.25.
Evolent Health (NYSE:EVH) last released its earnings results on Wednesday, May 9th. The technology company reported $0.02 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.06. The business had revenue of $139.70 million for the quarter, compared to analysts’ expectations of $140.89 million. Evolent Health had a negative return on equity of 2.16% and a negative net margin of 12.11%. The firm’s revenue was up 31.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. sell-side analysts anticipate that Evolent Health will post -0.33 earnings per share for the current fiscal year.
In other news, Director Unitedhealth Group Inc sold 2,861,065 shares of the stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $19.23, for a total transaction of $55,018,279.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Frank J. Williams sold 47,314 shares of the stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $24.00, for a total transaction of $1,135,536.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,149,979 shares of company stock valued at $60,641,618. 4.82% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Paloma Partners Management Co boosted its holdings in shares of Evolent Health by 92.8% during the fourth quarter. Paloma Partners Management Co now owns 32,768 shares of the technology company’s stock worth $403,000 after purchasing an additional 15,769 shares during the period. US Bancorp DE boosted its holdings in shares of Evolent Health by 30.5% during the fourth quarter. US Bancorp DE now owns 28,263 shares of the technology company’s stock worth $348,000 after purchasing an additional 6,609 shares during the period. Virtu Financial LLC purchased a new stake in shares of Evolent Health during the fourth quarter worth about $172,000. Cortina Asset Management LLC boosted its holdings in shares of Evolent Health by 43.4% during the fourth quarter. Cortina Asset Management LLC now owns 413,406 shares of the technology company’s stock worth $5,085,000 after purchasing an additional 125,053 shares during the period. Finally, American International Group Inc. boosted its holdings in shares of Evolent Health by 15.3% during the fourth quarter. American International Group Inc. now owns 40,266 shares of the technology company’s stock worth $495,000 after purchasing an additional 5,335 shares during the period.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.